ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL

June 4-8, 2021; Online at https://conferences.asco.org/am
In this head-to-head, randomized phase III trial, acalabrutinib proved to be noninferior to ibrutinib for PFS and demonstrated a more favorable safety profile, particularly regarding cardiovascular events.
Format: Microsoft PowerPoint (.ppt)
File Size: 466 KB
Released: June 9, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Amer M. Zeidan, MBBS, discusses novel and investigational therapies for treating patients with myelodysplastic syndromes (MDS) in this commentary from Clinical Care Options (CCO)

Amer Zeidan, MBBS Released: November 22, 2021

Downloadable PDF with expert answers to clinicians’ questions on the care of patients with lymphomas during COVID-19, from Clinical Care Options (CCO)

John Allan, MD Sandra E. Kurtin, PhD, ANP-C, AOCN Released: November 18, 2021

In this commentary from Clinical Care Options (CCO), Dr. Jennifer Woyach discusses patient education and shared decision making in CLL

Jennifer Woyach, MD Released: November 17, 2021

Gain key clinical insights with this slideset from Clinical Care Options (CCO) on how ADCs use for cancer therapy can cause ocular toxicity

Asim V. Farooq, MD Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue